olivLaw · US equity research
Scholar Rock Holding Corp SRRK
Biological Products, (No Diagnostic Substances) · SIC 2836 · Vertical: Biological Products, (No Diagnostic Substances) (SIC 2836)
Scholar Rock is a biopharmaceutical company developing apitegromab, an antibody that inhibits myostatin, for spinal muscular atrophy (SMA) and other rare neuromuscular diseases. The company is approaching an FDA decision with a September 30, 2026 action date that could move it from development to commercial stage, after a net loss of $215.4 million in the first half of 2026.
At the close of 05 Nov 2026, Scholar Rock Holding Corp (SRRK) stock was 45.50 USD (−1.28% on the day), with market capitalisation 5.5 bn USD, beta 1.30, 52-week range 28.80–60.04 USD. Latest reported quarter (Q2 2026): revenue of 0 USD, net income of -109.9 m USD, diluted EPS -0.84 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 55.1
- strong (55–70)
- Bollinger (20, 2)
- 38.86 – 45.83
- in the upper half of the band · %B 0.95 · band width 16.5%
- SMA 50 / 200
- 47.38 / 48.19
- downtrend (price < SMA50 < SMA200)
- MACD (12, 26, 9)
- -0.40 / -1.20
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | +7.2% | −1.1% | +8.3 pp | — |
| 3 months | −13.6% | −0.5% | −13.1 pp | — |
| 6 months | −2.0% | +4.4% | −6.4 pp | — |
| Year to date | +3.3% | +12.3% | −9.0 pp | — |
| 1 year | +62.6% | +13.5% | +49.0 pp | +2.1% |
| 3 years | +273.9% | +76.4% | +197.5 pp | +0.6% |
| 5 years | +60.2% | +63.7% | −3.5 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q2 2026 · 30 Jun 2026
Quarterly statements · USD
| Fiscal year | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | 0 ≈ | 0 | 0 | 0 ≈ |
| Research & development | 48.7 m | 50.4 m | 48.7 m | 62.4 m | 50.5 m | 46.9 m | 51.8 m | 58.2 m |
| Operating income | -64.8 m | -69.4 m | -77.1 m | -112.1 m | -103.6 m | -91.9 m | -102.0 m | -108.9 m |
| Depreciation & amortisation | 446.0 k ≈ | 395.0 k | 393.0 k | 417.0 k ≈ | 423.0 k ≈ | 425.0 k | 335.0 k | 297.0 k ≈ |
| Interest expense | 1.7 m | 1.6 m | 1.8 m | 1.2 m | 1.3 m | 2.5 m | 2.3 m | 4.5 m |
| Net income | -64.5 m | -66.5 m | -74.7 m | -110.0 m | -102.2 m | -91.0 m | -105.5 m | -109.9 m |
| Diluted EPS | -0.66 | -0.61 ≈ | -0.67 | -0.98 | -0.90 | -0.76 ≈ | -0.83 | -0.84 |
| Operating cash flow | -52.5 m ≈ | -49.5 m | -78.7 m | -76.9 m ≈ | -68.9 m ≈ | -75.5 m | -82.1 m | -70.3 m ≈ |
| Capex | 31.0 k ≈ | 22.0 k | 271.0 k | 215.0 k ≈ | 84.0 k ≈ | 32.0 k | 68.0 k | 1.0 k ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 20.5 m | 15.4 m | 18.8 m | 33.2 m | unavailable | unavailable | 0 |
| Revenue YoY | unavailable | unavailable | −24.8% | +22.2% | +76.4% | unavailable | unavailable | unavailable |
| Net income | -49.3 m | -51.0 m | -86.5 m | -131.8 m | -134.5 m | -165.8 m | -246.3 m | -377.9 m |
| Net income YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| Diluted EPS | unavailable | unavailable | -2.81 | -3.59 | -2.26 | -1.99 | -2.47 | -3.29 |
| Diluted EPS YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| net % | unavailable | -248.9% | -561.5% | -700.5% | -405.2% | unavailable | unavailable | unavailable |
| Free cash flow | 23.1 m | -66.2 m | -64.4 m | -132.0 m | -133.8 m | -145.3 m | -201.0 m | -300.6 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 323.5 m USD
- Financial debt
- 99.7 m USD
- Net debt
- -223.8 m USD
- Equity
- 245.5 m USD
- Total assets
- 404.3 m USD
- Debt / equity
- 0.41x
- Current ratio
- 6.95x
- ROE
- -123.1%
- ROA
- -86.0%
- FCF margin
- unavailable
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 15.4 m | 18.8 m | 33.2 m | — | — | 0 | SEC (XBRL)· 03 Mar 2026verified |
| Research & development | 74.1 m | 108.5 m | 124.4 m | 121.9 m | 184.6 m | 208.4 m | SEC (XBRL)· 03 Mar 2026verified |
| Operating income | -86.9 m | -129.9 m | -134.4 m | -171.3 m | -252.1 m | -384.6 m | SEC (XBRL)· 03 Mar 2026verified |
| Depreciation & amortisation | 1.5 m | 2.6 m | 3.0 m | 2.8 m | 1.9 m | 1.7 m | SEC (XBRL)· 03 Mar 2026verified |
| EBITDA | -85.4 m ≈ | -127.3 m ≈ | -131.4 m ≈ | -168.5 m ≈ | -250.1 m ≈ | -383.0 m ≈ | SEC (XBRL)· 03 Mar 2026derived |
| Interest expense | 400.0 k | 2.1 m | 4.7 m | 6.5 m | 6.8 m | 6.9 m | SEC (XBRL)· 03 Mar 2026verified |
| Net income | -86.5 m | -131.8 m | -134.5 m | -165.8 m | -246.3 m | -377.9 m | SEC (XBRL)· 03 Mar 2026verified |
| Diluted EPS | -2.81 | -3.59 | -2.26 | -1.99 | -2.47 | -3.29 | SEC (XBRL)· 03 Mar 2026verified |
| Weighted average diluted shares | 30.7 m | 36.7 m | 59.6 m | 83.3 m | 99.8 m | 114.7 m | SEC (XBRL)· 03 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 160.4 m | 212.8 m | 103.3 m | 101.9 m | 177.9 m | 323.5 m | SEC (XBRL)· 03 Mar 2026verified |
| Current assets | 344.4 m | 265.3 m | 328.0 m | 288.2 m | 451.2 m | 385.1 m | SEC (XBRL)· 03 Mar 2026verified |
| Property, plant & equipment, net | 8.1 m | 9.6 m | 7.4 m | 4.6 m | 2.8 m | 1.7 m | SEC (XBRL)· 03 Mar 2026verified |
| Total assets | 388.3 m | 304.4 m | 358.2 m | 311.0 m | 474.9 m | 404.3 m | SEC (XBRL)· 03 Mar 2026verified |
| Accounts payable | 3.4 m | 4.4 m | 4.0 m | 3.5 m | 10.1 m | 10.3 m | SEC (XBRL)· 03 Mar 2026verified |
| Short-term debt | — | 1.6 m | — | 1.3 m | — | — | SEC (XBRL)· 19 Mar 2024verified |
| Long-term debt | 24.7 m | 48.4 m | 49.7 m | 48.7 m | 50.1 m | 99.7 m | SEC (XBRL)· 03 Mar 2026verified |
| Current liabilities | 42.6 m | 64.3 m | 36.4 m | 32.7 m | 46.9 m | 55.4 m | SEC (XBRL)· 03 Mar 2026verified |
| Total liabilities | 127.5 m | 132.4 m | 97.9 m | 85.8 m | 106.3 m | 158.8 m | SEC (XBRL)· 03 Mar 2026verified |
| Equity | 260.8 m † | 172.1 m † | 260.2 m † | 225.2 m † | 368.6 m † | 245.5 m † | SEC (XBRL)· 03 Mar 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -60.3 m | -126.8 m | -132.7 m | -145.2 m | -200.9 m | -300.0 m | SEC (XBRL)· 03 Mar 2026verified |
| Capex | 4.1 m | 5.2 m | 1.1 m | 71.0 k | 98.0 k | 602.0 k | SEC (XBRL)· 03 Mar 2026verified |
| Free cash flow | -64.4 m ≈ | -132.0 m ≈ | -133.8 m ≈ | -145.3 m ≈ | -201.0 m ≈ | -300.6 m ≈ | SEC (XBRL)· 03 Mar 2026derived |
| Investing cash flow | -63.5 m | 134.3 m | -171.7 m | 41.1 m | -76.1 m | 218.7 m | SEC (XBRL)· 03 Mar 2026verified |
| Financing cash flow | 247.8 m | 45.0 m | 194.8 m | 102.6 m | 353.0 m | 228.4 m | SEC (XBRL)· 03 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 4 of at least 6
- score weight coverage: 29.2% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
05 Nov 2026Source: olivLaw, closing series
Market cap: 5.5 bn USD
Key indicators
Coverage and freshness
Score by group
29% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · input data missing
- Peers: EV/EBITDAunavailable · the base of the ratio is not positive
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
no valuation method could be computed
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 4 of at least 6; score weight coverage: 29.2% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | -477.3% | 0 (vs peers) | 36% |
| Net margin · Quality | unavailable | unavailable | — |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | unavailable | unavailable | — |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | -38.0x | 0 (on a fixed band) | 21% |
| Current ratio · Balance sheet | 7.0x | 100 (on a fixed band) | 14% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | -5.4% | 0 (on a fixed band) | 29% |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet40/100 · 2/3 factors with a value
- Growth· partialunavailable · 0/2 factors with a value
- Quality· partial0/100 · 1/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partial0/100 · 1/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
SCHOLAR ROCK HOLDING CORPORATION (SRRK). Latest full fiscal year: 2025; data up to 2026-06-30.
Figures computed from the financial statements: revenue 0 USD in 2025; ROE -167.8%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (indicators available: 4 of at least 6; score weight coverage: 29.2% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Current ratio: 7.0x
What contradicts it
- ROIC: -477.3%
- Interest coverage: -38.0x
- FCF yield: -5.4%
Not assessed (insufficient data or a ratio without meaning): Net margin, FCF conversion, Revenue CAGR 3Y, EPS CAGR 3Y, Net debt / EBITDA, P/E (TTM), EV/EBITDA, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Biological Products, (No Diagnostic Substances) (SIC 2836) · same industry (4-digit SIC) · compared with 39 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| AMGNAmgen Inc. | 258.8 bn | 27.7 | 78.4% | 24.1% | +10.0% | +39% / +77% |
| GILDGilead Sciences, Inc. | 216.4 bn | — | -22.3% | -12.5% | +2.4% | +39% / +128% |
| MRNAModerna, Inc. | 103.2 bn | — | -39.0% | -141.4% | −39.9% | +895% / +233% |
| RVMDRevolution Medicines, Inc. | 43.2 bn | — | -93.6% | -946.8% | unavailable | +157% / +756% |
| BIIBBiogen Inc. | 37.6 bn | 108.8 | 1.9% | 3.4% | +2.2% | +40% / +9% |
| EXELExelixis, Inc. | 17.8 bn | 21.7 | 44.3% | 35.5% | +7.0% | +65% / +234% |
| KYMRKymera Therapeutics, Inc. | 10.9 bn | — | -27.3% | -341.8% | −16.7% | +89% / +517% |
| KRYSKrystal Biotech, Inc. | 8.9 bn | 40.8 | 17.5% | 47.9% | +33.9% | +38% / +188% |
| CGONCG Oncology, Inc. | 5.7 bn | — | -26.4% | -3,602.7% | +254.7% | +45% / unavailable |
| SRRKScholar Rock Holding Corporation | 5.5 bn | — | -167.8% | — | unavailable | +63% / +274% |
| ADPTAdaptive Biotechnologies Corporation | 4.3 bn | — | -37.1% | -23.7% | +54.8% | +36% / +513% |
| BEAMBeam Therapeutics Inc. | 2.7 bn | — | -11.3% | -73.9% | +120.0% | +2% / −8% |
| RXRXRecursion Pharmaceuticals, Inc. | 2.2 bn | — | -48.7% | -697.1% | +26.9% | −24% / −49% |
| BCRXBiocryst Pharmaceuticals, Inc. | 2.0 bn | — | — | -37.4% | +94.1% | +6% / +30% |
| MAZEMaze Therapeutics, Inc. | 1.8 bn | — | -37.3% | -5,343.6% | unavailable | −14% / unavailable |
| MGTXMeiraGTx Holdings plc | 817.3 m | 12.1 | 72.2% | 19.9% | +144.6% | +3% / +63% |
| SLDBSolid Biosciences Inc. | 689.8 m | — | -76.9% | — | −40.6% | +14% / +119% |
| DNAGinkgo Bioworks Holdings, Inc. | 634.6 m | — | -56.3% | -260.0% | −25.1% | +7% / −81% |
| CADLCandel Therapeutics, Inc. | 615.2 m | — | -81.8% | — | 0.0% | +69% / +794% |
| AUTLAutolus Therapeutics plc | 335.4 m | — | -133.0% | -238.7% | +644.9% | −11% / −71% |
| OCGNOcugen, Inc. | 277.0 m | — | — | -1,367.6% | +8.8% | −34% / +111% |
| SABSSab Biotherapeutics, Inc. | 267.5 m | — | -11.3% | — | −100.0% | −26% / −70% |
| PLXProtalix BioTherapeutics, Inc. | 202.2 m | 10.9 | 31.2% | 23.5% | −1.2% | +41% / +66% |
| PALIPalisade Bio, Inc. | 202.2 m | — | -51.4% | -6,388.2% | unavailable | −45% / −88% |
| ARTVArtiva Biotherapeutics, Inc. | 201.9 m | — | -36.6% | — | −100.0% | +10% / unavailable |
1- and 3-year price returns: for SRRK from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Scenarios are not available. input data missing
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
Scholar Rock is a biopharmaceutical company developing apitegromab, an antibody that inhibits myostatin, for spinal muscular atrophy (SMA) and other rare neuromuscular diseases. The company is approaching an FDA decision with a September 30, 2026 action date that could move it from development to commercial stage, after a net loss of $215.4 million in the first half of 2026 23.
SWOT
Strengths
- The proprietary platform targeting latent growth factor forms is patented and offers high selectivity against structurally related proteins.
- Apitegromab has a positive pivotal Phase 3 result and a defined FDA action date, bringing the company close to its first commercial product.
- The balance sheet is supported by roughly $492 million in cash and marketable securities at June 30, 2026, with additional funds from the ATM program.
Weaknesses
- The company has no history of product sales and has not generated product revenue to date.
- Net losses have been recorded since inception, and the accumulated deficit now exceeds one billion dollars.
- Reliance on third parties for manufacturing and fill-finish has caused a significant approval delay.
Opportunities
- FDA approval could allow an immediate U.S. launch and could support expansion to other countries.
- Studies in FSHD and other neuromuscular diseases could extend the market beyond SMA.
- Partnerships for early-stage programs and for combinations with metabolic therapies could bring additional funding.
Threats
- The FDA decision could be delayed or restricted if manufacturing issues are not resolved.
- The European timeline could slip if the inspection classification remains unclear or if EMA requests additional information.
- European pricing and reimbursement could limit potential revenue even after an approval.
Risks
- FDA approval delayhigh
If the problems at a third-party facility are not resolved, approval of apitegromab could be postponed beyond the September 2026 action date.
- Inspection classificationhigh
The OAI classification of a facility could affect the EMA process if the authority requests additional assurance.
- Launch without commercial experiencemedium
The company has never sold a product and could face difficulty building sales teams and market access capabilities.
- Need for additional fundingmedium
Continued losses could require additional capital, which could dilute current shareholders.
- Share price volatilitylow
The share price is volatile, and investors could lose part or all of their investment, as the filing warns.
Investment thesis
What would need to be true (bull case)
- If the FDA approves apitegromab by the September 2026 date, the company could become the first to launch a myostatin inhibitor for SMA.
- The cash position and ATM funding could cover launch costs if approval arrives on time.
- Expansion into FSHD and other rare diseases could increase the platform's value beyond a single product.
What would break the thesis
- If the second fill-finish facility or the Catalent facility does not receive a favorable classification, the timeline could slip well beyond September 2026.
- High net losses could continue even after approval if sales grow slowly.
- European pricing and reimbursement negotiations could significantly reduce potential revenue.
What to watch
- FDA decision on apitegromab and the Catalent inspection classificationSeptember 2026
- EMA timeline and possible addition of the second fill-finish facility to the MAA2026
- Use of the ATM program and evolution of cash and marketable securitiesQ3 2026
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
Scholar Rock is a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy and other rare, severe and debilitating neuromuscular diseases 1. Its foundation is a proprietary platform that targets the latent, precursor forms of growth factors in the TGFβ superfamily, enabling selective monoclonal antibodies 1. The company has not generated product sales revenue to date and reported a net loss of $377.9 million for fiscal 2025 1.
The lead product, apitegromab, is an investigational fully human monoclonal antibody that inhibits myostatin activation by selectively binding its pro and latent forms in skeletal muscle 1. The Phase 3 SAPPHIRE study met its primary endpoint, and the BLA was submitted to the FDA in January 2025 with priority review, while the EMA validated the MAA in March 2025 1. After a Complete Response Letter in September 2025, the BLA was resubmitted in March 2026 and accepted with a September 30, 2026 PDUFA date 2.
Segments
Market context
The target market is rare neuromuscular disease, where there is significant unmet need for therapies that address progressive muscle weakness 1. The FSHD market, with approximately 30000 individuals in the U.S. and Europe, is one of the indications under review 1. European market access depends on pricing and reimbursement negotiations that can be lengthy and uncertain 1.
Commercial activity depends on the outcome of the FDA review and on a possible EMA approval, which in turn depends on the inspection classification of a third-party fill-finish facility 23. The market outlook remains closely tied to the FDA decision due by September 2026.
Trends
- Muscle-targeted therapy beyond SMNtailwind
Research indicates that targeting myostatin can increase muscle mass, which could open opportunities across several neuromuscular diseases, not only SMA 1.
- Regulatory pressure on manufacturingheadwind
Observations at a third-party fill-finish facility led to a CRL and an OAI classification, which delayed the commercial timeline 12.
- European pricing and reimbursementheadwind
Price and reimbursement negotiations in the EU are lengthy and vary country by country, which could limit patient access 1.
- Capital markets fundingmixed
The company has raised funds through its at-the-market program, which supports operations while adding dilution pressure for shareholders 3.
Competitive position
The company states that apitegromab would be the first myostatin inhibitor with a statistically significant Phase 3 outcome, which could offer an advantage over other approaches 23. Existing SMN-targeted treatments remain the main alternative for patients, and the exact competitive landscape is not detailed in the analysed sources 1.
Traditional approaches that inhibit mature myostatin or the ActRIIb receptor face selectivity limitations, which could lead other companies to pursue similar targets 1. The company argues its latent-targeting platform could reduce effects on related growth factors 1.
- SMN-targeted therapies for SMA
Approved SMA treatments with which apitegromab could be used in combination or as an alternative, as described in the company filing
- Traditional myostatin inhibitors
Antibodies targeting mature myostatin or the ActRIIb receptor, approaches the company describes as having selectivity limitations
- Other anti-myostatin programs in development
Clinical or preclinical programs in the field, not identified in the analysed sources
- FSHD therapies
Treatment options in development for FSHD, an indication targeted by the FORGE study
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
- Scholar Rock Shares Rise 9.1% After FDA Approves ISEMBYLD for Spinal Muscular AtrophyYahoo Finance — News · 14 Sept 2026 · EN
- STAT+: Scholar Rock wins FDA approval for first drug to target SMA muscle lossSTAT News · 11 Sept 2026 · EN
The latest news item in our archive is from 14 Sept 2026; the newest SEC filing is from 15 Sept 2026. The press archive comes from the RSS feeds we follow and does not necessarily cover the latest event — the filings alongside do.
SEC filings
- Current report15 Sept 2026Regulation FD disclosure
- Current report14 Sept 2026Regulation FD disclosure · Other events · Financial statements and exhibits
- Current report06 Aug 2026Other events · Financial statements and exhibits
- Quarterly report06 Aug 2026
- Current report06 Aug 2026Results of operations
- Current report05 Jun 2026Shareholder vote
- Quarterly report07 May 2026
- Current report07 May 2026Results of operations · Regulation FD disclosure · Financial statements and exhibits
- Proxy statement22 Apr 2026
- Current report31 Mar 2026Regulation FD disclosure · Other events · Financial statements and exhibits
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / Scholar Rock Holding Corp · 03 Mar 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / Scholar Rock Holding Corp · 06 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / Scholar Rock Holding Corp · 06 Aug 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.